Heterogeneity of plasma tissue factor pathway inhibitor
- PMID: 7841311
Heterogeneity of plasma tissue factor pathway inhibitor
Abstract
Much of tissue factor pathway inhibitor (TFPI) in plasma is bound to lipoproteins. The major form of TFPI associated with low density lipoproteins (LDL) is 34 kDa, whereas that associated with high density lipoproteins (HDL) is 41 kDa and appears in part to represent a mixed disulphide complex between TFPI and apolipoprotein AII. The native and recombinant TFPI produced by mammalian cells in tissue culture and the TFPI released by heparin in vivo, however, are 34 kDa. Western blotting with antibodies raised against specific TFPI peptides and cation exchange chromatography under denaturing conditions of partially purified plasma TFPI suggest that only a fraction of TFPI circulating in plasma is in the form of the full length molecule, the remainder consisting of variably carboxyl-terminal truncated forms. Electrospray mass spectrometry of the isolated 34 kDa form of plasma TFPI, which predominantly circulates bound to LDL, confirms that it lacks a substantial portion of the carboxyl-terminus including at least a portion of the third Kunitz-type domain.
Similar articles
-
Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.Blood Coagul Fibrinolysis. 1993 Oct;4(5):713-20. Blood Coagul Fibrinolysis. 1993. PMID: 8292720
-
Tissue factor pathway inhibitor; its structure, function and clinical significance.Pol J Pharmacol. 1996 Jan-Feb;48(1):67-72. Pol J Pharmacol. 1996. PMID: 9112630
-
Structure and biology of tissue factor pathway inhibitor.Thromb Haemost. 2001 Oct;86(4):959-72. Thromb Haemost. 2001. PMID: 11686353 Review.
-
The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.J Mol Biol. 1997 Jun 13;269(3):395-407. doi: 10.1006/jmbi.1997.1029. J Mol Biol. 1997. PMID: 9199408
-
Tissue factor pathway inhibitor: proposed heparin recognition region.Blood Coagul Fibrinolysis. 1995 Jun;6 Suppl 1:S50-6. Blood Coagul Fibrinolysis. 1995. PMID: 7647222 Review.
Cited by
-
Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S.Res Pract Thromb Haemost. 2018 Jan;2(1):93-104. doi: 10.1002/rth2.12058. Epub 2017 Dec 29. Res Pract Thromb Haemost. 2018. PMID: 29354797 Free PMC article.
-
Expression of tissue factor pathway inhibitor by endothelial cells and platelets.Transfus Apher Sci. 2008 Feb;38(1):9-14. doi: 10.1016/j.transci.2007.12.001. Epub 2008 Feb 7. Transfus Apher Sci. 2008. PMID: 18261960 Free PMC article. Review.
-
Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach.J Thromb Haemost. 2025 Feb;23(2):480-491. doi: 10.1016/j.jtha.2024.10.028. Epub 2024 Nov 12. J Thromb Haemost. 2025. PMID: 39536817 Free PMC article.
-
The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.Blood. 2010 Aug 26;116(8):1344-51. doi: 10.1182/blood-2009-10-246686. Epub 2010 May 17. Blood. 2010. PMID: 20479289 Free PMC article.
-
Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.Blood. 2007 Mar 1;109(5):1931-7. doi: 10.1182/blood-2006-07-037283. Epub 2006 Nov 2. Blood. 2007. PMID: 17082321 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous